ADC Therapeutics SA
(NYSE : ADCT)

( )
ADCT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.58%143.130.7%$858.08m
PFEPfizer Inc. -1.24%37.450.9%$834.37m
MRKMerck & Co., Inc. -1.09%77.980.7%$641.32m
BMYBristol-Myers Squibb Co. -1.58%58.731.0%$576.80m
ABBVAbbVie, Inc. -1.45%82.701.9%$573.06m
LLYEli Lilly & Co. -6.92%131.891.1%$497.00m
AZNAstraZeneca Plc -1.11%52.481.2%$212.96m
GSKGlaxoSmithKline Plc 0.43%35.370.2%$153.30m
NVSNovartis AG -3.84%80.950.2%$144.70m
NVONovo Nordisk A/S -2.41%67.970.1%$68.84m
RGENRepligen Corp. -0.96%175.847.1%$66.03m
RPRXRoyalty Pharma Plc -2.32%37.870.2%$62.66m
TPTXTurning Point Therapeutics, Inc. 6.88%100.080.0%$54.47m
SNYSanofi -3.52%47.400.2%$47.65m
AMAGAMAG Pharmaceuticals, Inc. 0.15%13.7022.1%$46.92m

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.